Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial
CONCLUSION: Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg). Both medication therapies were safe in patients, and the increased dose of monotherapy showed more side effects than the combination therapy.PMID:38275031 | DOI:10.2174/0118715257274373231211060714
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Authors: An Viet Tran Bao Lam Thai Tran Nghia Minh Bui Anh Tan To Le Diem Thi Nguyen Son Kim Tran Toan Hoang Ngo Source Type: research
More News: Cardiology | Cardiovascular | Chemistry | Cholesterol | Clinical Trials | Crestor | Eyes | Heart | Hematology | Rosuvastatin | Study | Vietnam Health | Vytorin | Zetia